商務部廣州召開珠三角地區外資企業圓桌會 Nike(NKE.US)等逾30間外企出席
國家商務部副部長兼國際貿易談判副代表凌激在廣州主持舉行珠三角地區外資企業圓桌會,認爲目前全球貿易投資障礙增加,國際投資放緩。不過,中國經濟韌性強,將依法保障外資企業國民待遇、平等參與標準制定,加強智識財產權保護,不斷擴大高水準對外開放,爲全球產供鏈穩定與發展發揮正面作用。
埃克森美孚(XOM.US)、巴斯夫、現代汽車、Nike(NKE.US)、亨氏(KHC.US)、IBM(IBM.US)、西門子及沃爾瑪(WMT.US)等超過30間外資企業代表有份參與今次會議。與會企業稱,雖然外部不確定因素帶來困難,但仍堅定在中國的長期投資,積極參與粵港澳大灣區建設。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.